$6.810
-0.147 (-2.16%)At close
PRTG News
PRTG Events
Portage Biotech Rebrands as AlphaTON Capital and Introduces TON Digital Asset Treasury
AlphaTON Capital, formerly Portage Biotech (PRTG), announced a financing to acquire about $100M TON tokens and establish a specialized digital asset treasury company dedicated to building a strategic TON reserve and "providing public markets access to Telegram's rapidly expanding ecosystem of more than a billion monthly active users." The company stated: "AlphaTON Capital is executing a treasury strategy focused on acquiring TON, managing network infrastructure, and incubating leading applications within Telegram's ecosystem. This strategic initiative represents the company's commitment to supporting the growth of open-source, decentralized applications and infrastructure, while providing shareholders with exposure to one of the fastest-growing segments of the social media and digital asset markets." The new ticker symbol "ATON" is effective as of the opening of the market on September 4 and initial financing to acquire about $100M TON tokens and start the corporate treasury is expected to close on or about September 5, the company noted. Enzo Villani, Founder and CEO of Alpha Transform Holdings, who will join the company as Executive Chairman and Chief Investment Officer, commented: "We are witnessing the natural evolution of financial markets as traditional finance converges with digital assets and blockchain infrastructure. The integration of platforms like Telegram with blockchain represents one of the most significant market opportunities since the introduction of Bitcoin. By bridging traditional markets with this emerging ecosystem, we are positioning our shareholders to participate in the next major phase of digital asset adoption."
Portage regains full compliance with Nasdaq continued listing requirements
Portage Biotech announced that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.
Portage Biotech, Compedica enter mutual subscription agreement
Portage Biotech announced that on June 5, Portage and Compedica Holdings entered a mutual Subscription Agreement. Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501 shares of Compedica with a value of $4.29 per share, in a transaction valued at $5,000,000. After the transaction, Compedica will own 27.4% of the issued and outstanding ordinary shares of Portage. The Portage ordinary shares were sold pursuant to an exemption under the Securities Act of 1933, as amended, under Regulation S, and were issued as "restricted stock". Under the terms of the agreement, if Portage enters into an equity funding arrangement, subject to the working capital requirements of Portage and unless agreed otherwise by the parties in writing, Portage will use not less than 50% of net funds received to subscribe for new Compedica equity at a price of $4.29 per share, the intended use of proceeds to be to support the continued development of the Compedica device and its commercialization.
Portage Biotech's PORT-7 shows efficacy in mesothelioma preclinical study
Portage Biotech reports confirmatory preclinical efficacy data for PORT-7, a selective adenosine A2B receptor inhibitor. The new data in a murine mesothelioma model demonstrated single agent activity for PORT-7 that was superior to treatment with single agent anti-PD1 antibody. Moreover, the combination of PORT-7 and anti-PD1 was superior to treatment with either anti-PD1 or PORT-7 alone. Immunohistochemistry of the tumors revealed the formation of tertiary lymphoid structures in the mice receiving the combination. This indication of a favorable immune response was accompanied by increases in immune effector cells in mice treated with the combination. Mesothelioma is an aggressive cancer with limited treatment options in need of novel approaches to overcome immune resistance. Portage is making preparations to commence a first-in-human clinical trial with PORT-7. In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor. Portage's plan is to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial.
Portage Biotech presents preclinical data for PORT-7
Portage Biotech presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both single agent activity for PORT-7, and a dramatic greater than 90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma. Immunohistochemistry of the tumors revealed a significant infiltration of both CD3 and CD45 positive immune effector cells. Mesothelioma is an aggressive cancer with limited treatment options in need of novel approaches to overcome immune resistance. To the company's knowledge, this is the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage is making preparations to commence a first-in-human clinical trial with PORT-7. In parallel, Portage is advancing the dose escalation of PORT-6, a potent and selective inhibitor of the A2A adenosine receptor. Portage's plan is to ultimately co-administer PORT-6 with PORT-7 in the ongoing ADPORT-601 trial. This will mark the first time two highly selective A2A and A2B antagonists are combined in patients, with the aim of achieving a complete blockade of adenosine-induced immunosuppression in the tumor microenvironment. This approach is designed to fully neutralize adenosine-mediated immune suppression, enhance anti-tumor responses, and broaden the impact of immunotherapy in solid tumors.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.